Tau phosphorylated at different epitopes (pTau) have instead emerged as the most promising blood-based biomarkers in AD, and there are now several commercially available, adequately performing ultrasensitive plasma immunoassays detecting pTau181 that can discriminate between individuals with AD and controls with an AUC close to or over 0.95–7. The gene discussed is MAPT; the disease is Alzheimer disease.